Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell save search
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published: 2023-09-27 (Crawled : 14:00) - biospace.com/
ACET | $2.02 -11.01% -12.38% 930K
|
Health Technology
|
| O: 0.7%
H: 4.86%
C: 0.0%
cancer cell immunotherapy meeting platform
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
INAB | $1.04 4.0% 3.85% 130K
|
|
| O: 3.36%
H: 3.25%
C: -6.5%
day cell city research
CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio
Published: 2023-09-25 (Crawled : 21:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: -3.28%
H: 5.93%
C: 4.24%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.32%
H: 1.81%
C: 1.23%
companies t-cell therapy growth market
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
Published: 2023-09-20 (Crawled : 12:00) - globenewswire.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -0.3%
H: 0.61%
C: -4.58%
vir-1388 vaccine cell hiv
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
Published: 2023-09-18 (Crawled : 11:00) - globenewswire.com
KYMR | $35.16 4.15% 3.98% 620K
|
Health Technology
|
| O: 1.0%
H: 1.92%
C: -0.78%
kt-333 fda t-cell treatment designation therapeutics
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-09-18 (Crawled : 09:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.25%
H: 0.38%
C: -0.32%
yescarta t-cell treatment response therapy study
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Published: 2023-09-11 (Crawled : 12:00) - globenewswire.com
LYEL | $2.34 -1.68% -1.71% 910K
|
Professional, Scientific, and T...
|
| O: 4.4%
H: 7.88%
C: 5.26%
t-cell cell therapy platform
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
COYA | News | $8.53 3.52% 3.4% 30K
|
|
| O: 0.93%
H: 19.86%
C: 11.09%
cell protein therapeutics potential
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
Published: 2023-09-06 (Crawled : 20:00) - globenewswire.com
CRVS | $1.43 5.15% 4.9% 140K
|
Health Technology
|
| O: 2.39%
H: 6.07%
C: -23.36%
cpi-818 fda cell pharmaceuticals meeting trial
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies
Published: 2023-08-31 (Crawled : 14:30) - biospace.com/
COYA | News | $8.53 3.52% 3.4% 30K
|
|
| O: -0.85%
H: 3.45%
C: 1.44%
biomarker publication sclerosis cell blood therapeutics potential
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
Published: 2023-08-28 (Crawled : 14:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.03%
H: 0.56%
C: -0.68%
partnership cell car-t program technology therapy platform
CAR T-cell Therapy: Genetically Modifying the Immune System to Attack Blood Cancer and Clinical Applications in Nursing Practice
Published: 2023-08-23 (Crawled : 13:30) - nanthealth.com
NHIQ | $0.341 16.76% 110
|
Information
|
| O: -2.5%
H: 0.0%
C: 0.0%
t-cell cancer blood system
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
Published: 2023-08-17 (Crawled : 15:00) - biospace.com/
MRKR | $4.24 -1.62% -1.65% 13K
|
Consumer Services
|
| O: -1.54%
H: 4.53%
C: -1.56%
institute cell research car-t technology therapeutics
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
Published: 2023-08-16 (Crawled : 12:00) - globenewswire.com
MBIO | $0.3819 -0.55% -1.05% 200K
|
Health Technology
|
| O: 5.53%
H: 0.0%
C: -9.23%
FBIO | $1.81 2.26% 2.21% 440K
|
Health Technology
|
| O: 1372.45%
H: 1.87%
C: -3.85%
mb-106 cell ongoing car-t trial therapy
City of Hope researchers develop a CAR T cell therapy for advanced ovarian cancer
Published: 2023-08-10 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
| Email alert
Add to watchlist
hope cancer cell city therapy
HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
Published: 2023-08-10 (Crawled : 13:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 0.02%
H: 0.37%
C: -2.78%
t-cell treatment trial
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Published: 2023-08-09 (Crawled : 11:00) - globenewswire.com
CGEM | $18.06 1.01% 1.0% 700K
|
|
| O: 4.0%
H: 0.0%
C: 0.0%
cln-978 cell trial
CAR T-Cell Therapy Market size to grow at a CAGR of 13.44% from 2022 to 2027; Growing Awareness Regarding CAR T-cell Therapy to boost the market growth- Technavio.
Published: 2023-08-09 (Crawled : 08:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.11%
H: 0.53%
C: 0.53%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.07%
H: 0.73%
C: 0.36%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.14%
H: 0.8%
C: 0.43%
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.61%
H: 1.07%
C: -0.5%
AUTL | $4.8 -0.83% -0.83% 1.2M
|
Health Technology
|
| O: -2.02%
H: 3.44%
C: 2.75%
t-cell growing therapy market
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Published: 2023-07-29 (Crawled : 20:20) - prnewswire.com
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
| Email alert
Add to watchlist
drug t-cell food treatment response
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
Published: 2023-07-26 (Crawled : 11:00) - globenewswire.com
MRKR | $4.24 -1.62% -1.65% 13K
|
Consumer Services
|
| O: 1.14%
H: 9.01%
C: -3.94%
cell car-t therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.